154 related articles for article (PubMed ID: 2924329)
1. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.
Reissmann T; Voegeli R; Pohl J; Hilgard P
Cancer Immunol Immunother; 1989; 28(3):179-84. PubMed ID: 2924329
[TBL] [Abstract][Full Text] [Related]
2. Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression.
Reissmann T; Hilgard P; Voegeli R; Zeller J
J Cancer Res Clin Oncol; 1989; 115(6):525-30. PubMed ID: 2606928
[TBL] [Abstract][Full Text] [Related]
3. Oxazaphosphorine effects in L 5222 rat leukemia.
Pohl J; Reissmann T; Voegeli R
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
[TBL] [Abstract][Full Text] [Related]
4. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
5. An experimental model for meningeal leukemia in rats (L5222). Effect of treatment with BCNU and cyclophosphamide.
Fiebig HH; Zeller WH; Schmähl D
Int J Cancer; 1976 Nov; 18(5):710-6. PubMed ID: 992902
[TBL] [Abstract][Full Text] [Related]
6. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.
Uckun FM; Chandan-Langlie M; Dockham PA; Aeppli D; Sladek NE
Leuk Lymphoma; 1994 May; 13(5-6):417-28. PubMed ID: 8069187
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
Mokyr MB; Colvin M; Dray S
Int J Immunopharmacol; 1985; 7(1):111-22. PubMed ID: 3922904
[TBL] [Abstract][Full Text] [Related]
9. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.
Skórski T; Kawalec M
Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151
[TBL] [Abstract][Full Text] [Related]
10. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
Nagarkatti M; Kaplan AM
J Immunol; 1985 Aug; 135(2):1510-7. PubMed ID: 3159794
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors.
Zeller WJ; Berger MR; Matys R; Schuhmacher J
Invest New Drugs; 1984; 2(2):175-80. PubMed ID: 6469512
[TBL] [Abstract][Full Text] [Related]
12. Early induction of immune resistance against leukemia in mice after lethal irradiation followed by syngeneic bone marrow transplantation and injection of syngeneic leukocytes.
Skórski T; Kawalec M; Kawiak J
Transplantation; 1991 Apr; 51(4):843-7. PubMed ID: 2014540
[TBL] [Abstract][Full Text] [Related]
13. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
Kawalec M; Skórski T; Kawiak J
Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
[TBL] [Abstract][Full Text] [Related]
14. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
Skórski T; Kawalec M
Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130
[TBL] [Abstract][Full Text] [Related]
15. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.
Schomburg A; Menzel T; Hadam M; Duensing S; Körfer A; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Jun; 4(2):58-65. PubMed ID: 1515095
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of the transplantable acute leukemia L5222 in rats.
Zeller WJ; Ivankovic S; Schmähl D
Cancer Res; 1975 May; 35(5):1168-74. PubMed ID: 1120307
[TBL] [Abstract][Full Text] [Related]
17. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Barker E; Mokyr MB
Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the antimetastatic effect of a single low dose of cyclophosphamide on rat lymphoma.
Matar P; Rozados VR; Roggero EA; Bonfil RD; Scharovsky OG
Tumour Biol; 1998; 19(2):69-76. PubMed ID: 9486558
[TBL] [Abstract][Full Text] [Related]
19. Induction of immune resistance against L1210 lymphatic leukemia in mice after lethal irradiation and reconstruction with fetal liver cells.
Skórski T; Ratajczak MZ; Kawalec M; Kawiak J
Folia Histochem Cytobiol; 1991; 29(3):121-4. PubMed ID: 1794437
[TBL] [Abstract][Full Text] [Related]
20. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
